Therapeutic cancer vaccines targeting MAGE-A3 are currently being developed and undergoing clinical trials to activate the patients’ immune systems to recognize and eliminate tumor cells expressing MAGE-A3 (39, 40). This evidence concerns the gene MAGEA3 and neoplasm.